New clinical trial firm formed following 3-company merger

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Kirtchanut)
(Image: Getty/Kirtchanut)

Related tags: Clinical trial sites, CNS

Three organizations have merged to form Apex Innovative Sciences, an independent clinical trial site operator focused on Phase I-IV studies for central nervous system indications and other therapeutic areas, including neurology, psychiatry, addiction, and others.

CNS Network and the Hassman Research Institute (HRI) recently completed a strategic merger to form Apex Innovative Sciences (Apex), which in turn acquired the Clinical Trial Centers Alliance (The Alliance).

James Castro, managing director of FocalPoint Partners (FPP), said the investment bank approached each business owner with the consolidation strategy. Speaking to the deal rationale, Castro told us CA-based CNS Networks provides Phase II and III inpatient clinical trial services, with expertise in clinical neuroscience indications, such as schizophrenia.

Said Castro, “Phase II and III inpatient studies for these complex clinical neuroscience studies involves an acute subject population which not many sites can manage well. CNS can fill studies with subjects quickly given its proprietary database of over 150,000 potential study candidates.”

Supplementing these services, Castro said the Hassman Research Institute is ‘largely recognized’ for its early phase work and has broader experience in various indications, including addiction, general medicine, dermatology, clinical neuroscience, among others.

The third of the recently merged companies, the Clinical Trials Centers Alliance (The Alliance), has “an expansive base of relationships with pharma and biotech sponsors,” ​added Castro.

“The company identifies new studies and ‘pitches’ its third-party network of sites to provide site-level clinical research services. The Alliance often combines CNS’s and HRI’s complementary services to win new, large, national studies,”​ he said.

The combined entity will operate under the Apex Innovative Sciences name and is currently centralizing The Alliance’s database across all the organizations. Over the next several months, the new company also will look to acquire additional sites, said Castro.

“Apex Innovative Sciences will look to separately accelerate the growth of its Acute Psychiatric Hospital,” ​he added. “Behavioral health companies have already demonstrated interest in separately purchasing the APH from Apex.”

Dr. Howard Hassman, Apex CEO said in a statement: “This combination is the culmination of years of collaboration between our organizations in complex clinical trial studies.”

Bison Capital Partners also participated with an equity investment to help expand Apex’s behavioral health treatment facility programs.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars